There are currently 1239 clinical trials in Seattle, Washington looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Washington, Seattle Children's Hospital, Fred Hutchinson Cancer Research Center and University of Washington Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Helping Ovarian Cancer Patients Cope With Their Illness (HOPE)
NCT06666218
Recruiting
This clinical trial compares the effect of the Helping Ovarian Cancer Patients Cope with Their Disease (HOPE) intervention to usual care for the reduction of hopelessness and helplessness in patients with ovarian cancer that has come back after a period of improvement (recurrent). Patients with recurrent ovarian cancer are at high risk for increased death and poor mental health outcomes, including depression and anxiety. Ovarian cancer is the deadliest of all gynecologic cancers, with a survival... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Recurrent Ovarian Carcinoma
Register for Updates
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
NCT04427384
Recruiting
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
Gender:
ALL
Ages:
All
Trial Updated:
02/26/2025
Locations: Virginia Mason, Seattle, Washington
Conditions: Brain Tumor, Recurrent, Brain Tumor, Brain Tumor, Primary, Brain Tumor - Metastatic, Brain Tumor, Adult: Glioblastoma, Brain Tumor, Adult Meningioma
Register for Updates
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06153251
Recruiting
The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: Swedish Medical Center, Seattle, Washington
Conditions: Relapsed and/or Refractory Multiple Myeloma
Register for Updates
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931
Recruiting
The primary objective of this study is to access the efficacy of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the total occurrences of all-cause mortality (ACM) and cardiovascular (CV) clinical events.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
02/26/2025
Locations: Research Site, Seattle, Washington
Conditions: Transthyretin Amyloid Cardiomyopathy
Register for Updates
Advancing Transplantation Outcomes in Children
NCT06055608
Recruiting
This is a pediatric kidney transplant study comparing the safety and efficacy of an immunosuppressive regimen of belatacept and sirolimus to tacrolimus and Mycophenolate Mofetil (MMF). Two hundred participants will be randomized (1:1) to one of two groups within 24 hours following the transplant procedure. The duration of the study from time of transplant to the primary endpoint is 12-24 months.
Gender:
ALL
Ages:
Between 13 years and 20 years
Trial Updated:
02/25/2025
Locations: Seattle Children's Hospital (Site #: 71041), Seattle, Washington
Conditions: Kidney Transplant
Register for Updates
Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
NCT06442475
Recruiting
This phase II trial tests the safety, side effects and effectiveness of mosunetuzumab in treating patients with slow growing (indolent) B-cell lymphoma. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
Register for Updates
Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.
NCT06247735
Recruiting
Study to investigate the efficacy and safety of two doses of K-808 (pemafribate) in subjects with PBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Liver Institute Northwest, Seattle, Washington
Conditions: Primary Biliary Cholangitis
Register for Updates
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
NCT04489719
Recruiting
This study investigates how well radium-223 works in treating patients with castration-resistant prostate cancer than has spread to the bones (bone metastases). Prostate cancer is the most common cancer in men and the second leading cause of cancer death. Furthermore, many men with notably advanced disease have been found to have abnormalities in DNA repair. The purpose of this research is to study the role of a DNA repair pathway in prostate cancer, specifically in response to administration of... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Register for Updates
CxBladder Surveillance of Intermediate and High-Risk Bladder Cancer Patients
NCT05080998
Recruiting
Surveillance for recurrence of urothelial carcinoma (UC) requires frequent cystoscopy, which is invasive, expensive and time-consuming. An accurate urinary biomarker has the potential to reduce the number of cystoscopies required during post-treatment surveillance. This is a prospective single arm multi-center study using the diagnostic CxBladder test with subjects previously diagnosed positive with primary or recurrent UC and who are undergoing a schedule of investigative cystoscopies and treat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: University of Washington School of Medicine, Seattle, Washington
Conditions: Urothelial Bladder Cancer
Register for Updates
Contraceptive Efficacy Study of Ovaprene
NCT06127199
Recruiting
This will be a multi-center, single arm, open-label study of Ovaprene, a non-hormonal intravaginal ring, to investigate the contraceptive effectiveness, safety and acceptability of Ovaprene.
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
02/25/2025
Locations: Seattle Clinical Research Center, Seattle, Washington
Conditions: Contraception
Register for Updates
Attention Bias Modification for the Improvement of Anxiety in Adolescent and Young Adult Cancer Survivors
NCT06682039
Recruiting
This clinical trial studies how well attention bias modification (ABM) improves anxiety in adolescent and young adult (AYA) cancer survivors. Cancer-related anxiety is the most prevalent mental health problem affecting AYA cancer survivors. Cancer-related anxiety is associated with long-term negative outcomes such as poor quality of life, depression, distress, substance use, sleep problems, fatigue, and pain. ABM uses techniques to help patients change the way they react to environmental trigger... Read More
Gender:
ALL
Ages:
Between 15 years and 29 years
Trial Updated:
02/24/2025
Locations: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Conditions: Childhood Hematopoietic and Lymphatic System Neoplasm, Childhood Malignant Solid Neoplasm
Register for Updates
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046
Recruiting
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: Virginia Mason Medical Center, Seattle, Washington +2 locations
Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Register for Updates